Visual field constriction on vigabatrin.
(1) Vigabatrin carries a high risk of concentric visual field constriction, sometimes associated with a drop in visual acuity.  The changes in the visual field appear to be irreversible.  (2) Consequently, vigabatrin can be considered only as a last resort for infantile spasms refractory to steroid therapy and for partial epilepsy refractory to other anticonvulsants.  (3) Patients treated with vigabatrin must have their visual fields monitored regularly.
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy; D005060:Europe; D006801:Humans; D007223:Infant; D013035:Spasm / Q000188:drug therapy; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000188:drug therapy; D014481:United States; D020888:Vigabatrin / Q000009:adverse effects / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced*; D014794:Visual Fields / Q000187:drug effects*
D000927:Anticonvulsants; D020888:Vigabatrin